User contributions
From 2009.igem.org
(Latest | Earliest) View (newer 100 | older 100) (20 | 50 | 100 | 250 | 500)
- 01:50, 22 October 2009 (diff | hist) Team:SupBiotech-Paris/Antitumor action (→Results [1,2])
- 01:38, 22 October 2009 (diff | hist) Team:SupBiotech-Paris/Treatement modeling (→First step : Tumour development according to time)
- 01:36, 22 October 2009 (diff | hist) Team:SupBiotech-Paris/Treatement modeling (→First step : Tumour development according to time)
- 01:32, 22 October 2009 (diff | hist) Team:SupBiotech-Paris/Tissue targeting (→Experimental method) (top)
- 01:31, 22 October 2009 (diff | hist) Team:SupBiotech-Paris/Tissue targeting (→Objective)
- 01:16, 22 October 2009 (diff | hist) Team:SupBiotech-Paris/Antitumor action (→Cancer cell line and reported gene)
- 01:15, 22 October 2009 (diff | hist) Team:SupBiotech-Paris/Antitumor action (→Cancer cell line and reported gene)
- 01:12, 22 October 2009 (diff | hist) Team:SupBiotech-Paris/Antitumor action (→Discussion)
- 01:02, 22 October 2009 (diff | hist) Team:SupBiotech-Paris/Ciblage Cellulaire (top)
- 00:57, 22 October 2009 (diff | hist) Team:SupBiotech-Paris/Antitumor action (→Experimental approach)
- 00:45, 22 October 2009 (diff | hist) Team:SupBiotech-Paris/Ethic (→The debate program)
- 00:39, 22 October 2009 (diff | hist) Team:SupBiotech-Paris/Ethic (→Summarization of reflections)
- 00:01, 22 October 2009 (diff | hist) Team:SupBiotech-Paris/Ethic (→Problematics related to the DVS project)
- 00:01, 22 October 2009 (diff | hist) Team:SupBiotech-Paris/Ethic (→Intellectual properties)
- 00:01, 22 October 2009 (diff | hist) Team:SupBiotech-Paris/Ethic (→The benefits/risks ratio)
- 23:58, 21 October 2009 (diff | hist) Team:SupBiotech-Paris/Ethic (→Evolution control synthetic biology products)
- 23:55, 21 October 2009 (diff | hist) Team:SupBiotech-Paris/Ethic
- 23:40, 21 October 2009 (diff | hist) Team:SupBiotech-Paris/Ethic
- 20:16, 21 October 2009 (diff | hist) Team:SupBiotech-Paris/Conclusion3
- 20:15, 21 October 2009 (diff | hist) Team:SupBiotech-Paris/Conclusion3
- 20:01, 21 October 2009 (diff | hist) Team:SupBiotech-Paris/Conclusion3Fr (→Conclusion)
- 17:24, 21 October 2009 (diff | hist) Team:SupBiotech-Paris/Conclusion3Fr
- 17:21, 21 October 2009 (diff | hist) Team:SupBiotech-Paris/Conclusion3Fr
- 17:20, 21 October 2009 (diff | hist) Team:SupBiotech-Paris/Conclusion3Fr
- 15:33, 21 October 2009 (diff | hist) Team:SupBiotech-Paris/Safety (→Judging form)
- 15:29, 21 October 2009 (diff | hist) Team:SupBiotech-Paris/Safety (→Laboratory safety)
- 15:29, 21 October 2009 (diff | hist) Team:SupBiotech-Paris/Safety (→Laboratory safety)
- 14:39, 21 October 2009 (diff | hist) Team:SupBiotech-Paris/Antitumor action (→Design of the fusion protein)
- 14:38, 21 October 2009 (diff | hist) Team:SupBiotech-Paris/Ciblage Cellulaire (→Design de la protéine de fusion)
- 14:36, 21 October 2009 (diff | hist) Team:SupBiotech-Paris/Antitumor action (→Design of the fusion protein)
- 14:34, 21 October 2009 (diff | hist) Team:SupBiotech-Paris/Ciblage Cellulaire (→Design de la protéine de fusion)
- 14:22, 21 October 2009 (diff | hist) Team:SupBiotech-Paris/Ciblage Cellulaire (→Contexte)
- 11:43, 21 October 2009 (diff | hist) Team:SupBiotech-Paris/Ciblage Cellulaire
- 11:39, 21 October 2009 (diff | hist) Team:SupBiotech-Paris/Concept2Fr (→L’internalisation du vecteur cellulaire et la libération du plasmide thérapeutique)
- 11:37, 21 October 2009 (diff | hist) Team:SupBiotech-Paris/Concept2 (→The internalization of the cell vector and the release of the therapeutic plasmid)
- 11:34, 21 October 2009 (diff | hist) Team:SupBiotech-Paris/Antitumor action
- 11:29, 21 October 2009 (diff | hist) Team:SupBiotech-Paris/Antitumor action
- 11:29, 21 October 2009 (diff | hist) Team:SupBiotech-Paris/Antitumor action
- 11:25, 21 October 2009 (diff | hist) Team:SupBiotech-Paris/Antitumor action (→Results)
- 11:16, 21 October 2009 (diff | hist) Team:SupBiotech-Paris/Antitumor action (→Results)
- 11:13, 21 October 2009 (diff | hist) Team:SupBiotech-Paris/Antitumor action
- 10:42, 21 October 2009 (diff | hist) Team:SupBiotech-Paris/Ciblage Cellulaire (→Conclusions)
- 10:31, 21 October 2009 (diff | hist) Team:SupBiotech-Paris/Ciblage Cellulaire (→Design de la protéine de fusion)
- 10:16, 21 October 2009 (diff | hist) Team:SupBiotech-Paris/Ciblage Cellulaire (→Contexte)
- 09:45, 21 October 2009 (diff | hist) Team:SupBiotech-Paris/Ciblage Cellulaire (→Conclusion [3,4,5,6,7,8,9])
- 09:43, 21 October 2009 (diff | hist) Team:SupBiotech-Paris/Ciblage Cellulaire (→Conclusion [3,4,5,6,7,8,9])
- 09:43, 21 October 2009 (diff | hist) Team:SupBiotech-Paris/Ciblage Cellulaire (→Conclusion [3,4,5,6,7,8,9])
- 09:42, 21 October 2009 (diff | hist) Team:SupBiotech-Paris/Ciblage Cellulaire (→Conclusion [3,4,5,6,7,8,9])
- 09:41, 21 October 2009 (diff | hist) Team:SupBiotech-Paris/Ciblage Cellulaire (→Résultats [1,2])
- 09:40, 21 October 2009 (diff | hist) Team:SupBiotech-Paris/Ciblage Cellulaire (→Conclusion [3,4,5,6,7,8,9])
- 03:55, 21 October 2009 (diff | hist) Team:SupBiotech-Paris/Antitumor action
- 02:20, 21 October 2009 (diff | hist) Team:SupBiotech-Paris/Ciblage Cellulaire (→Démarche expérimentale)
- 02:19, 21 October 2009 (diff | hist) Team:SupBiotech-Paris/Ciblage Cellulaire (→Démarche expérimentale)
- 02:18, 21 October 2009 (diff | hist) Team:SupBiotech-Paris/Ciblage Cellulaire (→Design de la protéine de fusion)
- 02:16, 21 October 2009 (diff | hist) Team:SupBiotech-Paris/Ciblage Cellulaire (→Objectif)
- 02:15, 21 October 2009 (diff | hist) Team:SupBiotech-Paris/Ciblage Cellulaire (→Objectif)
- 02:14, 21 October 2009 (diff | hist) Team:SupBiotech-Paris/Ciblage Cellulaire (→Contexte)
- 02:13, 21 October 2009 (diff | hist) Team:SupBiotech-Paris/Ciblage Cellulaire (→Le Ciblage cellulaire)
- 02:02, 21 October 2009 (diff | hist) Team:SupBiotech-Paris/Concept1Fr (→Le vecteur tissulaire)
- 01:35, 21 October 2009 (diff | hist) Team:SupBiotech-Paris/Ciblage Cellulaire (→Résultats [1,2])
- 01:09, 21 October 2009 (diff | hist) Team:SupBiotech-Paris/Ciblage Cellulaire (→Résultats)
- 01:01, 21 October 2009 (diff | hist) Team:SupBiotech-Paris/Ciblage Cellulaire (→Plasmide antitumoral)
- 00:25, 21 October 2009 (diff | hist) Team:SupBiotech-Paris/Ciblage Cellulaire (→Résultats)
- 00:19, 21 October 2009 (diff | hist) Team:SupBiotech-Paris/Ciblage Cellulaire (→Plasmide antitumoral)
- 23:54, 20 October 2009 (diff | hist) Team:SupBiotech-Paris/Ciblage Cellulaire (→Conclusion)
- 23:39, 20 October 2009 (diff | hist) Team:SupBiotech-Paris/Ciblage Tissulaire (→Conclusion)
- 23:34, 20 October 2009 (diff | hist) Team:SupBiotech-Paris/Ciblage Tissulaire (→Conclusion)
- 22:55, 20 October 2009 (diff | hist) Team:SupBiotech-Paris/Ciblage Cellulaire (→Conclusion)
- 22:37, 20 October 2009 (diff | hist) Team:SupBiotech-Paris/Conclusion1Fr (→Conclusion) (top)
- 22:33, 20 October 2009 (diff | hist) Team:SupBiotech-Paris/Concept3Fr (→L’encapsidation au sein du vecteur cellulaire [1,2,3,4,5,6])
- 22:19, 20 October 2009 (diff | hist) Team:SupBiotech-Paris/Equipe (→L’équipe)
- 22:14, 20 October 2009 (diff | hist) Team:SupBiotech-Paris/Biobricks
- 22:04, 20 October 2009 (diff | hist) Team:SupBiotech-Paris/Concept2 (→The cell vector deliverance in the target organ [1,2,8])
- 22:01, 20 October 2009 (diff | hist) Team:SupBiotech-Paris/Concept2 (→The cell vector: The lambda phage [1,2])
- 21:57, 20 October 2009 (diff | hist) Team:SupBiotech-Paris/Concept1 (→To summarize…)
- 21:54, 20 October 2009 (diff | hist) Team:SupBiotech-Paris/Concept1 (→Cell wall and tissue vector envelope)
- 21:49, 20 October 2009 (diff | hist) Team:SupBiotech-Paris/Concept (→The Double Vector System)
- 21:40, 20 October 2009 (diff | hist) Team:SupBiotech-Paris/HomeEn (→The "DVS" Project)
- 21:24, 20 October 2009 (diff | hist) Team:SupBiotech-Paris/Remerciement (→Les étudiants)
- 21:12, 20 October 2009 (diff | hist) Team:SupBiotech-Paris/Concept1Fr (→Les tissus cibles du DVS [6,7])
- 21:10, 20 October 2009 (diff | hist) Team:SupBiotech-Paris/Concept1Fr (→Paroi cellulaire et enveloppe du vecteur tissulaire)
- 21:08, 20 October 2009 (diff | hist) Team:SupBiotech-Paris/Concept1Fr (→Mécanisme de détournement du système immunitaire)
- 20:56, 20 October 2009 (diff | hist) Team:SupBiotech-Paris/Conclusion1 (→Conclusion)
- 20:52, 20 October 2009 (diff | hist) Team:SupBiotech-Paris/Gene therapies (→Gene therapy [1])
- 20:48, 20 October 2009 (diff | hist) Team:SupBiotech-Paris/Current therapies (→Current therapies)
- 19:22, 20 October 2009 (diff | hist) Team:SupBiotech-Paris/Sûreté (→La bio-terreur)
- 19:13, 20 October 2009 (diff | hist) Team:SupBiotech-Paris/Sûreté (→Libération accidentelle)
- 19:10, 20 October 2009 (diff | hist) Team:SupBiotech-Paris/Sûreté (→Introduction)
- 19:05, 20 October 2009 (diff | hist) Team:SupBiotech-Paris/Sûreté (→Introduction)
- 19:05, 20 October 2009 (diff | hist) Team:SupBiotech-Paris/Sûreté (→Introduction)
- 19:04, 20 October 2009 (diff | hist) Team:SupBiotech-Paris/Sûreté (→Introduction)
- 19:01, 20 October 2009 (diff | hist) Team:SupBiotech-Paris/Sûreté (→Avant Propos)
- 18:58, 20 October 2009 (diff | hist) Team:SupBiotech-Paris/Sûreté (→Avant Propos)
- 18:54, 20 October 2009 (diff | hist) Team:SupBiotech-Paris/Sûreté (→Formulaire pour les juges)
- 15:18, 20 October 2009 (diff | hist) Team:SupBiotech-Paris/Conclusion1 (→Conclusion)
- 13:10, 20 October 2009 (diff | hist) Team:SupBiotech-Paris/Biobricks
- 13:08, 20 October 2009 (diff | hist) Team:SupBiotech-Paris/Biobricks
- 13:06, 20 October 2009 (diff | hist) Team:SupBiotech-Paris/Biobricks
- 13:05, 20 October 2009 (diff | hist) Team:SupBiotech-Paris/Biobricks
- 13:02, 20 October 2009 (diff | hist) Team:SupBiotech-Paris/Biobricks
(Latest | Earliest) View (newer 100 | older 100) (20 | 50 | 100 | 250 | 500)